Serum Renalase Level as A Marker of Activity and Severity in Lupus Nephritis Cases
DOI:
https://doi.org/10.14738/aivp.95.10983Keywords:
Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Renalase (RNLS)Abstract
- Introduction:
Lupus nephritis (LN) is a substantial risk factor for death and morbidity in patients with Systemic Lupus Erythematosus (SLE) (SLE). Despite excellent immunosuppressive therapy, it nevertheless leads to a disproportionate percentage of persons developing chronic kidney disease (CKD) or end-stage renal disease (ESRD). Renalase is a distinctive cytokine-like protein generated by the kidneys that promote cell survival. It has been recently linked to the etiology of LN and may be an ideal candidate as a sensitive biomarker for flare-ups and LN remission.
-Aim of the work:
The purpose of this study was to evaluate the utility of human serum renalase as a biomarker for assessing disease activity and severity in SLE, as well as to evaluate if it can be used as a sensitive biomarker in this capacity.
-Methods:
This study consists of around 23 healthy controls and 46 individuals with LN. These participants were separated into two equal groups according to disease activity as determined by the SLEDAI (SLE Disease Activity Index): 23 cases with LN who had disease activity and 23 cases who did not. The concentration of human serum Renalase (RNLS) was evaluated using a very sensitive commercial enzyme immunoassay that captures renalase from serum using (RNLS) antibody.
- Results:
Renalase concentrations were significantly greater in LN cases than in healthy controls (P-value <0.001). Additionally, cases with active LN exhibited significantly greater serum renalase concentrations than those with inactive LN (P-value <0.005). Serum renalase concentrations were positively connected with 24-h urine protein excretion, SLEDAI, ESR, CRP, and ds-DNA but were negatively related to serum C3 and the class (particularly in the proliferative type) (Class III, IV, more than class V).
-Conclusion:
Serum renalase levels were associated with disease symptoms in LN and may serve as a biomarker for disease activity in LN.
References
C. C. Mok, S. S. K. Tang, C. H. To, and M. Petri, "Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups," Arthritis and Rheumatism, vol. 52, no. 9, pp. 2774–2782, 2005.
Danila MI, Pons-Estel GJ, Zhang J, et al: Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology 48:542–545, 2009.
Mok CC, Kwok RC, Yip PS: Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 65(8):2154–2160, 2013.
C. C. Mok, "Update on emerging drug therapies for systemic lupus erythematosus," Expert Opinion on Emerging Drugs, vol. 15, pp. 53–70, 2010.
Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005; 115:1275–1280. PMID: 15841207.
Desir GV, Wang L, Peixoto AJ. Human renalase: a review of its biology, function, and implications for hypertension. J Am Soc Hypertens. 2012; 6:417–426. doi: 10.1016/j.jash.2012.09.002 PMID: 23107895
Wang L, Velazquez H, Moeckel G, Chang J, Ham A, Lee HT, et al. Renalase Prevents AKI Independent of Amine Oxidase Activity. J Am Soc Nephrol. 2014; 25:1226–1235. doi: 10.1681/ASN.2013060665 PMID: 24511138
Lee HT, Kim JY, Kim M, Wang P, Tang L, Baroni S, et al. Renalase protects against ischemic AKI. J Am Soc Nephrol. 2013; 24:445–455. doi: 10.1681/ASN.2012090943 PMID: 23393318
Przybylowski P, Koc-Zorawska E, Malyszko JS, Mysliwiec M, Malyszko J. Renalase and endothelial dysfunction in heart transplant recipients. Transplant Proc. 2013; 45:394–396. doi: 10.1016/j. transproceed.2012.02.042 PMID: 23375328
Przybylowski P, Malyszko J, Kozlowska S, Malyszko J, Koc-Zorawska E, Mysliwiec M. Serum renalase depends on kidney function but not on blood pressure in heart transplant recipients. Transplant Proc. 2011; 43:3888–3891. doi: 10.1016/j.transproceed.2011.08.075 PMID: 22172866
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012a; 64:2677–86.
Johnson S. European League Against Rheumatism and American College of Rheumatology present new SLE classification criteria at the 2017 ACR/ARHP annual meeting. Presentation at: ACR/ARHP 2017 Annual Meeting; November 3-8, 2017; San Diego, CA.
Urowitz MB, Gladman DD. Measures of disease activity and damage in SLE. Baillieres Clin Rheumatol 1998; 12 :405–13.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. J Arthritis Rheum 1992; 35:630–640.
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi L-M, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15: 241–250, 2004.
Xue J, Yang J, Yang L, Zhou S, Ji C, Wang X, et al. Dickkopf-1 is a biomarker for systemic lupus erythematosus and active lupus nephritis. J Immunol Res 2017; 2017:6861575.
Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017; 12:825–835. doi: 10.2215/CJN.05780616. Epub 2016 Nov.
arto N, Bertolaccini ML, Calabuig E, Hughes GRV, Khamashta MA. AntiC1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:444–448.
Qi C, Wang L, Zhang M, Shao X, Chang X, Fan Z, et al. (2015) Serum Renalase Levels Correlate with Disease Activity in Lupus Nephritis. PLoS ONE 10(10): e0139627. doi: 10.1371/journal.pone.0139627
Desir GV, Tang L, Wang P, Li G, Sampaio-Maia B, Quelhas-Santos J, et al. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc. 2012; 1: e2634.].
Zbroch E, Malyszko J, Malyszko J, Koc-Zorawska E, Mysliwiec M. Renalase in peritoneal dialysis patients is not related to blood pressure, but to dialysis vintage. Perit Dial Int. 2012; 32:348–351. doi: 10.3747/pdi.2011.00118 PMID: 22641741,
Zbroch E, Malyszko J, Malyszko JS, Koc-Zorawska E, Mysliwiec M. Renalase, a novel enzyme involved in blood pressure regulation, is related to kidney function but not to blood pressure in hemodialysis patients. Kidney Blood Press Res. 2012; 35:395–399. doi: 10.1159/000338178 PMID: 22539018],
Howson JM, Cooper JD, Smyth DJ, Walker NM, Stevens H, She JX, et al. Evidence of gene-gene interaction and age-at-diagnosis effects in type 1 diabetes. Diabetes. 2012; 61:3012–3017. doi: 10.2337/ db11-1694 PMID: 22891215
Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009; 41:703–707. doi: 10.1038/ng.381 PMID: 19430480
Wallace C, Rotival M, Cooper JD, Rice CM, Yang JH, McNeill M, et al. Statistical colocalization of monocyte gene expression and genetic risk variants for type 1 diabetes. Hum Mol Genet. 2012; 21:2815–2824. doi: 10.1093/hmg/dds098 PMID: 22403184
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Yasser Gazar
This work is licensed under a Creative Commons Attribution 4.0 International License.
